BioInvent International: BioInvent Announces Additional Effi

One additional patient has developed a partial response (PR) and one patient has remained on stable disease for over 80 weeksThese long-lasting responses in hard-to-treat metastatic diseases, in patients

Related Keywords

Zeiten , Mecklenburg Vorpommern , Germany , United States , Stefan Klotter , Cecilia Hofvander , Martin Welschof , Bioinvent Internationalview , Bioinvent International Ab Nasdaq Stockholm , Bioinvent International , Bioinvent International Ab , Twitter , Merck Co Inc , Merck Sharp Dohme , Merck Sharp , Nasdaq Stockholm , Senior Director Investor , Stabile Ertr , Chart Profi Stefan Klotter , Blue Chips , Bioinvent , Nternational , Nnounces , Dditional , Efficacy , Data , Rom , Intravenous , Art , Hase , Trial , 206 , Olid , Rumors ,